Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.
Fiche publication
Date publication
mars 2023
Journal
BMC medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie, Pr PETIT Thierry
Tous les auteurs :
Courtinard C, Gourgou S, Jacot W, Carton M, Guérin O, Vacher L, Bertaut A, Le Deley MC, Pérol D, Marino P, Levy C, Uwer L, Perrocheau G, Schiappa R, Bachelot F, Parent D, Breton M, Petit T, Filleron T, Loeb A, Pélissier SM, Robain M, Delaloge S, Bellera C
Lien Pubmed
Résumé
Overall survival (OS) is the gold standard endpoint to assess treatment efficacy in cancer clinical trials. In metastatic breast cancer (mBC), progression-free survival (PFS) is commonly used as an intermediate endpoint. Evidence remains scarce regarding the degree of association between PFS and OS. Our study aimed to describe the individual-level association between real-world PFS (rwPFS) and OS according to first-line treatment in female patients with mBC managed in real-world setting for each BC subtype (defined by status for both hormone-receptor [HR] expression and HER2 protein expression/gene amplification).
Mots clés
Association, Breast cancer, Overall survival, Progression-free survival, Real-word data, Surrogacy
Référence
BMC Med. 2023 03 8;21(1):87